journal article·2021-10Open access

Repeated exposure of nosocomial pathogens to silver does not select for silver resistance but does impact ciprofloxacin susceptibility

Victor M. Villapún, Dario L. Balacco, Mark A. Webber, Thomas Hall, Morgan Lowther, Owen Addison, Sarah A. Kuehne, Liam M. Grover, Sophie C. Cox

Acta Biomaterialia· Volume 134

Abstract

The rise of antimicrobial resistant bacteria coupled with a void in antibiotic development marks Antimicrobial Resistance as one of the biggest current threats to modern medicine. Antimicrobial metals are being developed and used as alternative anti-infectives, however, the existence of known resistance mechanisms and limited data regarding bacterial responses to long-term metal exposure are barriers to widespread implementation. In this study, a panel of reference and clinical strains of major nosocomial pathogens were subjected to serial dosage cycles of silver and ciprofloxacin. Populations exposed to silver initially showed no change in sensitivity, however, increasingly susceptibility was observed after the 25th cycle. A control experiment with ciprofloxacin revealed a selection for resistance over time, with silver treated bacteria showing faster adaptation. Morphological analysis revealed filamentation in Gram negative species suggesting membrane perturbation, while sequencing of isolated strains identified mutations in numerous genes. These included those encoding for efflux systems, chemosensory systems, stress responses, biofilm formation and respiratory chain processes, although no consistent locus was identified that correlated with silver sensitivity. These results suggest that de novo silver resistance is hard to select in a range of nosocomial pathogens, although silver exposure may detrimentally impact sensitivity to antibiotics in the long term. STATEMENT OF SIGNIFICANCE: The adaptability of microbial life continuously calls for the development of novel antibiotic molecules, however, the cost and risk associated with their discovery have led to a drying up in the pipeline, causing antimicrobial resistance (AMR) to be a major threat to healthcare. From all available strategies, antimicrobial metals and, more specifically, silver showcase large bactericidal spectrum and limited toxic effect which coupled with a large range of processes available for their delivery made these materials as a clear candidate to tackle AMR. Previous reports have shown the ability of this metal to enact a synergistic effect with other antimicrobial therapies, nevertheless, the discovery of Ag resistance mechanisms since the early 70s and limited knowledge on the long term influence of silver on AMR poses a threat to their applicability. The present study provides quantitative data on the influence of silver based therapies on AMR development for a panel of reference and clinical strains of major nosocomial pathogens, revealing that prolonged silver exposure may detrimentally impact sensitivity to antibiotics.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bacterial biofilms and quorum sensing · Antibiotic Resistance in Bacteria · Pharmaceutical and Antibiotic Environmental Impacts

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. A review on antibiotic resistance: alarm bells are ringing
2. O'Neill · 2016
3. The true cost of antimicrobial resistance10.1136/bmj.f1493 ↗
4. Antibiotics and antibiotic resistance: a bitter fight against evolution10.1016/j.ijmm.2013.02.004 ↗
5. Society’s failure to protect a precious resource: antibiotics10.1016/S0140-6736(11)60401-7 ↗
6. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis10.1016/S1473-3099(17)30753-3 ↗
7. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe10.2807/ese.13.47.19045-en ↗
8. The continuing crisis in antibiotic resistance10.1016/S0924-8579(10)70003-0 ↗
9. Antimicrobial silver: uses, toxicity and potential for resistance10.1007/s10534-013-9645-z ↗
10. 1996
11. Exposure-related health effects of silver and silver compounds: a review
12. Silver and its compounds
13. History of the medical use of silver10.1089/sur.2008.9941 ↗
14. Antimicrobial silver in medicinal and consumer applications: a patent review of the past decade (2007–2017)10.3390/antibiotics7040093 ↗
15. Silver as an antimicrobial: facts and gaps in knowledge10.3109/1040841X.2012.713323 ↗
16. Lansdown · 2010
17. Using a chemical genetic screen to enhance our understanding of the antibacterial properties of silver10.3390/genes9070344 ↗
18. Bacterial resistance to silver in wound care10.1016/j.jhin.2004.11.014 ↗
19. Sütterlin · 2015
20. Silver nitrate resistant E. coli: report of case10.1097/00000658-196908000-00021 ↗
21. Antibacterial silver10.1155/MBD.1994.467 ↗
22. Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin: a new threat in burn units?10.1016/S0140-6736(75)91138-1 ↗
23. Bacterial antimicrobial metal ion resistance10.1099/jmm.0.023036-0 ↗
24. The silver cation (Ag+): antistaphylococcal activity, mode of action and resistance studies10.1093/jac/dks372 ↗
25. Silver resistance in Gram-negative bacteria: a dissection of endogenous and exogenous mechanisms10.1093/jac/dku523 ↗
26. Nano-strategies to fight multidrug resistant bacteria—“A Battle of the Titans10.3389/fmicb.2018.01441 ↗
27. Antibacterial synergy of silver nanoparticles with gentamicin and chloramphenicol against Enterococcus faecalis
28. Synergistic antibacterial effect of silver nanoparticles combined with ineffective antibiotics on drug resistant Salmonella typhimurium DT104
29. Co-selection of resistance to antibiotics, biocides and heavy metals, and its relevance to foodborne pathogens10.3390/antibiotics4040567 ↗
30. Role of rifampin for treatment of orthopedic implant–related staphylococcal infections: a randomized controlled trial10.1001/jama.279.19.1537 ↗
31. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections10.1111/j.1469-0691.2005.01230.x ↗
32. Treatment of staphylococcal implant infection with rifampicin-ciprofloxacin in stable implants10.1007/s004020000242 ↗
33. The expanding role of fluoroquinolones10.1067/mda.2003.12 ↗
34. Fluoroquinolones: mechanism of action, classification, and development of resistance10.1016/j.survophthal.2004.01.005 ↗
35. Wicked: the untold story of ciprofloxacin10.1371/journal.ppat.1006805 ↗
36. Resistance pattern of ciprofloxacin against different pathogens
37. Interplay of the quality of ciprofloxacin and antibiotic resistance in developing countries10.3389/fphar.2017.00546 ↗
38. Changes in susceptibility to ciprofloxacin in a community in northern Israel10.2165/00003495-199500492-00030 ↗
39. Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients10.2165/00003495-199500492-00031 ↗
40. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-199710.1093/jac/43.1.145 ↗
41. Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population
42. Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 200810.1007/s40121-015-0095-5 ↗
43. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 201010.1128/AAC.06060-11 ↗
44. Prevalence of quinolone-resistant uropathogenic Escherichia coli in a tertiary care hospital in south Iran10.2147/IDR.S206966 ↗
45. Risk factors for quinolone-resistant Escherichia coli infection: a systematic review and meta-analysis
46. Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa10.1016/j.ejpb.2018.04.006 ↗
47. Bacterial resistance to silver nanoparticles and how to overcome it10.1038/s41565-017-0013-y ↗
48. Rifampicin-soaked silver polyester versus expanded polytetrafluoro-ethylene grafts for in situ replacement of infected grafts in a porcine randomised controlled trial10.1016/j.ejvs.2012.02.011 ↗
49. Kraken: ultrafast metagenomic sequence classification using exact alignments10.1186/gb-2014-15-3-r46 ↗
50. Standards · 2006
51. M26-A Methods for determining bactericidal activity of antimicrobial agents: approved guideline
52. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices10.1128/jcm.22.6.996-1006.1985 ↗
53. Microtiter dish biofilm formation assay
54. Trimmomatic: a flexible trimmer for Illumina sequence data10.1093/bioinformatics/btu170 ↗
55. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing10.1089/cmb.2012.0021 ↗
56. Prokka: rapid prokaryotic genome annotation10.1093/bioinformatics/btu153 ↗
57. Seemann · 2017
58. Identification of acquired antimicrobial resistance genes10.1093/jac/dks261 ↗
59. Basic local alignment search tool10.1016/S0022-2836(05)80360-2 ↗
60. Molecular basis for resistance to silver cations in Salmonella10.1038/5545 ↗
61. Mauve: multiple alignment of conserved genomic sequence with rearrangements10.1101/gr.2289704 ↗
62. ProgressiveMauve: multiple genome alignment with gene gain, loss and rearrangement10.1371/journal.pone.0011147 ↗
63. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update10.1093/nar/gky379 ↗
64. Field · 2010
65. Inactivation of the antibacterial and cytotoxic properties of silver ions by biologically relevant compounds10.1371/journal.pone.0094409 ↗
66. Comparison of methods to detect the in vitro activity of silver nanoparticles (AgNP) against multidrug resistant bacteria10.1186/s12951-015-0120-6 ↗
67. Antimicrobial properties of a novel silver-silica nanocomposite material10.1128/AEM.01658-08 ↗
68. Preventing implant-associated infections by silver coating10.1128/AAC.02934-15 ↗
69. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?10.1093/jac/dkm006 ↗
70. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli10.1128/AEM.02001-07 ↗
71. Rapid evolution of silver nanoparticle resistance in Escherichia coli10.3389/fgene.2015.00042 ↗
72. Cryptic silver resistance is prevalent and readily activated in certain Gram-negative pathogens10.1093/jac/dkx258 ↗
73. Chromosomal Sil system contributes to silver resistance in E. coli ATCC 873910.1007/s10534-018-0143-1 ↗
74. Synthesis and modification of bio-derived antibacterial Ag and ZnO nanoparticles by plants, fungi, and bacteria10.1016/j.drudis.2021.03.030 ↗
75. Silver as antibacterial agent: ion, nanoparticle, and metal10.1002/anie.201205923 ↗
76. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents10.3390/ijms19020444 ↗
77. Silver nanoparticles induce a triclosan-like antibacterial action mechanism in multi-drug resistant Klebsiella pneumoniae10.3389/fmicb.2021.638640 ↗
78. Antimicrobial silver: an unprecedented anion effect10.1038/srep07161 ↗
79. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli10.1007/s00253-009-2159-5 ↗
80. Towards understanding the antibacterial activity of Ag nanoparticles: electron microscopy in the analysis of the materials-biology interface in the lung
81. Antibacterial effects of biosynthesized silver nanoparticles on surface ultrastructure and nanomechanical properties of gram-negative bacteria viz. Escherichia coli and Pseudomonas aeruginosa10.1021/acsami.6b00161 ↗
82. 2018
83. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment10.1093/jac/45.3.353 ↗
84. Development and selection of low-level multi-drug resistance over an extended range of sub-inhibitory ciprofloxacin concentrations in Escherichia coli10.1038/s41598-020-65602-z ↗
85. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem10.1099/jmm.0.000873 ↗
86. An assessment of methods for measuring volumes of planktonic bacteria, with particular reference to television image analysis10.1111/j.1365-2672.1985.tb01435.x ↗
87. A novel algorithm for the determination of bacterial cell volumes that is unbiased by cell morphology10.1017/S1431927611012104 ↗
88. Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye10.1038/ja.2011.5 ↗
89. Emergence of antibiotic resistance from multinucleated bacterial filaments10.1073/pnas.1420702111 ↗
90. Consequences of long-term bacteria’s exposure to silver nanoformulations with different physico chemical properties10.2147/IJN.S208838 ↗
91. Identification of specific protein amino acid substitutions of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli ST131: a proteomics approach using mass spectrometry10.1038/s41598-019-45051-z ↗
92. Seemann · 2018
93. Bacitracin sensing in Bacillus subtilis10.1111/j.1365-2958.2008.06194.x ↗
94. Peptide antibiotic sensing and detoxification modules of Bacillus subtilis10.1128/AAC.00352-10 ↗
95. Identification of regions important for resistance and signalling within the antimicrobial peptide transporter BceAB of Bacillus subtilis10.1128/JB.00419-13 ↗
96. Thiol-based redox switches in prokaryotes10.1515/hsz-2015-0102 ↗
97. Ribonucleotide reductases: essential enzymes for bacterial life10.3389/fcimb.2014.00052 ↗
98. Role of a cysteine synthase in Staphylococcus aureus10.1128/JB.186.6.1579-1590.2004 ↗
99. Genetic determinants enabling medium-dependent adaptation to nafcillin in methicillin-resistant Staphylococcus aureus10.1128/mSystems.00828-19 ↗
100. Redox imbalance underlies the fitness defect associated with inactivation of the Pta-AckA pathway in Staphylococcus aureus10.1021/acs.jproteome.5b01089 ↗